Amgen's Repatha reduces first-time heart attack and stroke risk by 25%
TL;DR Summary
A study published in the New England Journal of Medicine shows that Amgen's cholesterol injection Repatha significantly reduces the risk of heart attacks, strokes, and cardiovascular death in high-risk individuals without prior events, outperforming traditional statin therapy.
- Amgen’s cholesterol shot prevented first heart attacks and strokes, more detailed data affirm statnews.com
- Amgen cholesterol drug cuts risk of first cardiac event by 25% Reuters
- Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV TCTMD.com
- PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke www.heart.org
- AHA25: Amgen's Repatha clears 25% mark in preventing first cardiac events FirstWord Pharma
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
1 min
vs 2 min read
Condensed
84%
229 → 37 words
Want the full story? Read the original article
Read on statnews.com